Inherited forms of mineralocorticoid hypertension

Hypertension

Volumn 28, Issue 6, 1996, Pages 927-936

  White, Perrin C ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

aldosterone; cytochrome P 450; hydroxysteroid dehydrogenases; mineralocorticoids hydroxylases

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 18 OXOHYDROCORTISONE; ALDOSTERONE; ANDROGEN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CORTICOTROPIN; CORTISONE; CORTODOXONE; CYTOCHROME P450; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN; SODIUM; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; STEROID 21 MONOOXYGENASE; SYNTHETASE; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADENOMA; ARTICLE; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LOW BIRTH WEIGHT; METABOLISM; NONHUMAN; PLACENTA WEIGHT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SOUTHERN BLOTTING; ZONA GLOMERULOSA;

EID: 0029847663     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.6.927     Document Type: Article

References (84)

1. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med. 1994;331:250-258.
2. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta hydroxylase isozymes. Endocr Rev. 1994;15:421-438.
3. Lin D, Sugawara T, Strauss JF, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science. 1995;267: 1828-1831.
4. Yanase T, Simpson ER, Waterman MR. 17 Alpha-hydroxylase/ 17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev. 1991;12:91-108.
5. Rosier A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet. 1992;42:827-834.
6. Pang S, Levine LS, Lorenzen F, Chow D, Pollack M, Dupont B, Genel M, New MI. Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1980;50:586-589.
7. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency: a study of 25 patients. J Clin Endocrinol Meiab. 1983; 56:222-229.
8. Griffing GT, Dale SL, Holbrook MM, Melby JC. 19-Nor-deoxycorticosterone excretion in primary aldosteronism and low renin hypertension. J Clin Endocrinol Meiab. 1983;56:218-221.
9. Ohta M, Fujii S, Ohnishi T, Okamoto M. Production of 19-oic-11-deoxycorticosterone from 19-oxo-11-deoxycorticosterone by cytochrome p-450(11)beta and nonenzymatic production of 19-nor-11-deoxycorticosterone from 19-oic-11-deoxycorticosterone. J Steroid Biochem. 1988;29:699-707.
10. Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Am J Dis Child. 1985;139:771-776.
11. Nadler JL, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab. 1985;60:896-899.
12. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (p-450(11) beta). J Biol Chem. 1989;264:20961-20967.
13. Chua SC, Szabo P, Vitek A, Grzeschik KH, John M, White PC. Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450C11). Proc Natl Acad Sci U S A. 1987;84:7193-7197.
14. Wagner MJ, Ge Y, Siciliano M, Wells DE. A hybrid cell mapping panel for regional localization of probes to human chromosome 8. Genomics. 1991;10:114-125.
15. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A. 1992;89: 8327-8331.
16. Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, Gill JR Jr, Feld L, Ganguly A, Laidlaw JC, Murnaghar DJ, Kaufman C, Stockigt JR, Ulick S, Lalovel JM. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2:66-74.
17. Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the human cyp11b2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A. 1992; 89:4996-5000.
18. Curnow KM, Tusie-Luna MT, Paseoe L, Natarajan R, Gu JL, Nadler JL, White PC. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol. 1991;5:1513-1522.
19. Helmberg A, Ausserer B, Kofler R. Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;75:1278-1281.
20. Curnow KM, Slutsker L, Vitek J, Cole T, Speiser PW, New MI, White PC, Pascoe L. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A. 1993;90:4552-4556.
21. Naiki Y, Kawamoto T, Mitsuuchi Y, Miyahara K, Toda K, Orii T, Imura H, Shizuta Y. A nonsense mutation (TGG [Trp116] - TAG [Stop] in CYP11B1 causes steroid 11beta-hydroxylase deficiency. J Clin Endocrinol Metab. 1993;77:1677-1682.
22. Geley S, Kapelari K, Johrer K, Peter M, Glatzl J, Vierhapper H, Sippell WG, White PC, Kofler R. CYP11B1 mutations causing congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. J Clin Endocrinol Metab. In press.
23. White PC, Dupont J, New MI, Leiberman E, Hochberg Z, Rosler A. A mutation in CYP11B1 (Arg-448 - His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 1991;87:1664-1667.
24. Nelson DR, Strobel HW. On the membrane topology of vertebrate cytochrome P-450 proteins. J Biol Chem. 1988;263:6038-6050.
25. Poulos TL. Modeling of mammalian P450s on basis of P450cam x-ray structure. Methods Enzymol. 1991;206:11-30.
26. Ravichandran KG, Boddupalli SS, Hasemann CA, Peterson JA, Deisenhofer J. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science. 1993;261:731-736.
27. Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am. 1994;23:341-357.
28. Kagimoto M, Winter JS, Kagimoto K, Simpson ER, Waterman MR. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol. 1988;2:564-570.
29. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA. 1987;6:439-448.
30. Sparkes RS, Klisak I, Miller WL. regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol. 1991;10:359-365.
31. Yanase T. 17 Alpha-hydroxylase/17,20-lyase defects. J Steroid Biochem Mol Biol. 1995;53:153-157.
32. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95:1109-1119.
33. New MI, Peterson RE. A new form of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1967;27:300-305.
34. New MI, Borelli P, eds. Dexamethasone-Suppressible Hyperaldosteronism. Rome, Italy: Serono Symposia; 1986.
35. Stockigt JR, Scoggins BA. Long term evolution of glucocorticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab. 1987; 64:22-26.
36. Hall CE, Gomez-Sanchez CE. Hypertensive potency of 18-oxocortisol in the rat. Hypertension. 1986;8:317-322.
37. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med. 1992;116:813-820.
38. O'Mahony S, Burns A, Murnaghan DJ. Dexamethasone-suppressible hyperaldosteronism: a large new kindred. J Hum Hypertens. 1989; 3:255-258.
39. Oberfield SE, Levine LS, Stoner E, Chow D, Rauh W, Greig F, Lee SM, Lightner E, Witte M, New MI. Adrenal glomerulosa function in patients with dexamethasone-suppressible hyperaldosteronism. J Clin Endocrinol Metab. 1981;53:158-164.
40. Ganguly A, Weinberger MH, Guthrie GP, Fineberg NS. Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism. Hypertension. 1984;6:563-567.
41. Melby JC. Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am. 1991;20:247-255.
42. Hamlet SM, Gordon RD, Gomez-Sanchez CE, Tunny TJ, Klemm SA. Adrenal transitional zone steroids, 18-oxo and 18-hydroxycortisol, useful in the diagnosis of primary aldosteronism, are ACTH-dependent. Clin Exp Pharmacol Physiol. 1988;15:317-322.
43. Ulick S, Chan CK, Gill JR Jr, Gutkin M, Letcher L, Mantero F, New MI. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1990; 71:1151-1157.
44. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Primary aldosteronism: hypertension with a genetic basis. Lancet. 1992;340: 159-161.
45. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
46. Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez-Sanchez CE, Gasc JM, Saez JM, Corvol P. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest. 1995;96:2236-2246.
47. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids. 1995;60:48-51.
48. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC, Connell JM. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci. 1995;88:563-570.
49. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res. 1995;21:437-442.
50. Fardella CE, Rodriguez H, Hum DW, Mellon SH, Miller WL. Artificial mutations in P450 c11AS (aldosterone synthase) can increase enzymatic activity: a model for low-renin hypertension? J Clin Endocrinol Metab. 1995;80:1040-1043.
51. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of Cortisol. J Clin Endocrinol Metab. 1979;49:757-764.
52. Oberfield SE, Levine LS, Carey RM, Greig F, Ulick S, New MI. Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1983;56:332-339.
53. Shackleton CH, Rodriguez J, Arteaga E, Lopez JM, Winter JS. Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf). 1985; 22:701-712.
54. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987; 2:821-824.
55. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology. 1989; 125:1046-1053.
56. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
57. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA. 1983;80:6056-6060.
58. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
59. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585.
60. Lakshmi V, Monder C. Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology. 1988;123: 2390-2398.
61. Agarwal AK, Monder C, Eckstein B, White PC. Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem. 1989;264:18939-18943.
62. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11 beta-hydroxysteroid dehydrogenase: structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991;266:16653-16658.
63. Rundle SE, Funder JW, Lakshmi V, Monder C. The intrarenal localization of mineralocorticoid receptors and 11 beta-dehydrogenase: immunocytochemical studies. Endocrinology. 1989;125:1700-1704.
64. Nikkila H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C, White PC. Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab. 1993;77:687-691.
65. Rusvai E, Naray-Fejes-Toth A. A new isoform of 11 beta-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem. 1993; 268:10717-10720.
66. Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology. 1993;132:2614-2621.
67. Yang K, Yu M. Evidence for distinct isoforms of 11-beta-hydroxysteroid dehydrogenase in the ovine liver and kidney. J Steroid Biochem Mol Biol. 1994;49:245-250.
68. Stewart PM, Murry BA, Mason JI. Type 2 11beta-hydroxysteroid dehydrogenase in human fetal tissues. J Clin Endocrinol Metab. 1994;78:1529-1532.
69. Agarwal AK, Mune T, Monder C, White PC. NAD+-dependent isoform of 11 beta hydroxysteroid dehydrogenase: cloning and characterization of cDNA from sheep kidney. J Biol Chem. 1994;269: 25959-25962.
70. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11-HSD type 2 enzyme. Mol Cell Endocrinol. 1994;105:R11-R17.
71. Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11β-hydroxysteroid dehydrogenase. Genomics. 1995;29:195-199.
72. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-399.
73. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263-2266.
74. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Licholai T, New MI. Several homozygous mutations in the gene for 11β-hydroxy steroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:3145-3150.
75. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347:88-91.
76. Mune T, White PC. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension. 1996;27: 1193-1199.
77. Obeyesekere VR, Ferrari P, Andrews RK, Wilson RC, New MI, Funder JW, Krozowski ZS. The R337C mutation generates a high Km 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995; 80:3381-3383.
78. Reinisch J, Simon NG, Karwo WG. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978; 202:436-438.
79. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet. 1993;341:355-357.
80. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993;341:339-341.
81. Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990;301:259-262.
82. Stewart PM, Rogerson FM, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 1995;80:885-890.
83. Lifton RP. Genetic determinants of human hypertension. Proc Natl Acad Sci U S A. 1995;92:8545-8551.
84. Smithies O, Kim HS. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci U S A. 1994;91:3612-3615.